Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

A Phase II, Open-Label, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

Alefacept is a drug tht may reduce the number of T cells in circulation. This drug has been used in the treatment of psoriasis, which is a skin disorder also caused by T cells, like chronic GVHD. Information from studies in psoriasis and in other patients with GVHD suggests that this drug may help to treat chronic GVHD. Chronic GVHD is a medical condition that can develop after allogeneic stem cell transplantation. It occurs when the donor immune cells (the "graft") attack and damage organs and tissue (the "host"). It is thought that T cells, a subtype of immune cells, are responsible for the tissue damage in chronic GVHD. In this research study we are looking to see how well Alefacept works in treating chronic GVHD that has not resolved after therapy with corticosteroids.

Study Overview

• Status: Terminated
• Conditions: Chronic Graft-versus-host Disease
• Intervention / Treatment: Drug: Alefacept

Detailed Description

• During the first week of treatment, participants will receive 2 doses of Alefacept intravenously (Day 1 and Day 4). During weeks 2-12, Alefacept will be given subcutaneously once weekly.
• On weeks 1, 2 and every other week through Week 12 of study treatment, participants will have a physical exam, blood tests, and be asked general health and specific questions about any problems they may be having.
• Every other week, participants will be asked to complete a questionnaire about their physical symptoms, activity level and emotional well being.

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • Dana-Farber Cancer Institute
  • Washington
    • Seattle, Washington, United States, 98109-1024
      • Fred Hutch Cancer Research Center
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Medical College of Wisconsin

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• 18 years of age or older
• Diagnosed with cGVHD according to NIH criteria
• Active cGVHD despite treatment with corticosteroids AND one additional immunosuppressive agent for at least 4 weeks, within 52 weeks of enrollment.
• Subject is a recipient of related or unrelated BMT or PBSCT
• Subject underwent transplantation at least 6 months prior to enrollment
• Subject is on stable immunosuppressive regimen for 2 weeks prior to enrollment. Adjustment of immunosuppressive medications to maintain a therapeutic level is permitted.
• Female of child bearing potential must have a negative pregnancy test prior to first dose of alefacept and must agree to practice effective contraception during the study. Men must also agree to use adequate contraception prior to study entry and for the duration of the study.
• Meets medication restriction requirements and agrees to follow medications restrictions during study.

Exclusion Criteria:

• Received donor lymphocyte infusions in the preceding 100 days
• Currently undergoing ECP
• Subject is recipient of related or unrelated UCB
• Subject has bronchiolitis obliterans, bronchiolitis obliterans with organizing pneumonia or cryptogenic organizing pneumonia as the sole manifestation of cGVHD
• Uncontrolled intercurrent active infection.
• Absolute neutrophil count < 1000/L
• AST, ALT or total bilirubin > 2x institutional upper limit of normal unless this is a manifestation of GVHD
• Recurrent or progressive malignancy at any time after HCT, as applicable for the individual malignancy
• Subject was in any clinical study within the last 30 days
• Receipt of 5 or more prior agents to treat cGVHD
• Known hypersensitivity to alefacept or any components of the study medication
• Known to be positive for human immunodeficiency virus (HIV) antibodies
• Currently enrolled in any other study for chronic GVHD treatment and receiving treatment under the study or previous participation in this study.
• Pregnant or nursing
• Concurrent illness which, in the opinion of the Investigator, may interfere with treatment or evaluation of safety

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Alefacept; Alefacept iv	Drug: Alefacept; Given intravenously Days 1 and 4 of Week 1, then subcutaneously once weekly for Weeks 2-12; Other Names: Amevive

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy	Proportion of patients with a favorable response, defined as a complete or partial remission at week 12 as compared to baseline in subjects with steroid refractory cGVHD.	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety of Alefacept Infusions in Patients With Chronic GVHD.	Assess the safety of alefacept in this patient population. The number of adverse events (including hematological and non-hematological safety events) will be used for safety assessment.	2 years

Collaborators and Investigators

• Sponsor: Dana-Farber Cancer Institute
• Collaborators: Astellas Pharma Inc; Brigham and Women's Hospital
• Investigators: Principal Investigator: Corey Cutler, MD, Dana-Farber Cancer Institute

Study record dates

Study Major Dates

• Study Start: October 1, 2010
• Primary Completion (Actual): August 1, 2012
• Study Completion (Actual): August 1, 2012

Study Registration Dates

• First Submitted: October 21, 2010
• First Submitted That Met QC Criteria: October 21, 2010
• First Posted (Estimate): October 22, 2010

Study Record Updates

• Last Update Posted (Estimate): August 13, 2013
• Last Update Submitted That Met QC Criteria: August 11, 2013
• Last Verified: August 1, 2013

More Information

Terms related to this study

• Keywords: GVHD; Amevive; Alefacept
• Additional Relevant MeSH Terms: Immune System Diseases; Graft vs Host Disease; Physiological Effects of Drugs; Immunologic Factors; Dermatologic Agents; Alefacept
• Other Study ID Numbers: 10-230